Search

Group. , Horizon Investigators of the Huntington Study. 2013. “A Randomized, Double-Blind, Placebo-Controlled Study of Latrepirdine in Patients With Mild to Moderate Huntington Disease. JAMA Neurol 2013;70:25-33.”. JAMA Neurol.

Fernandez, HH, A Vanagunas, P Odin, AJ Espay, RA Hauser, DG Standaert, K Chatamra, et al. 2013. “Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease Open-Label Study: Interim Results. Parkinsonism Relat Disord 2013;19:339-45.”. Parkinsonism Relat Disord.

Investigators, Writing Group for the NINDS Exploratory Trials in Parkinson Disease, K Kieburtz, BC Tilley, JJ Elm, D Babcock, RA Hauser, and . 2015. “Effect of Creatine Monohydrate on Clinical Progression in Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA 2015;313:584-93.”. JAMA.

Stegemoller, EL, P Schmidt, and . 2015. “How Should Pushing Off or the Use of Assistive Devices Be Incorporated in the Timed Up and Go for Persons With Parkinson Disease? Arch Phys Med Rehabil 2015;96:1728-32.”. Arch Phys Med Rehabil.

Kremens, D, RA Hauser, and ER Dorsey. 2014. “An Update on Parkinson’s Disease: Improving Patient Outcomes. Am J Med 2014;127:S3.”. Am J Med.

Investigators, The Parkinson Study Group QE3. 2014. “A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit. JAMA Neurol 2014;71:543-52.”. JAMA Neurol.

Hauser, RA. 2013. “PROUD Stands Tall: Delayed-Start Studies in Parkinson’s Disease. Lancet Neurol 2013;12:728-9.”. Lancet Neurol.

Stocchi, F, O Rascol, A Destee, N Hattori, RA Hauser, AE Lang, W Poewe, et al. 2013. “AFQ056 in Parkinson Patients With Levodopa-Induced Dyskinesia: 13-Week, Randomized, Dose-Finding Study. Mov Disord 2013;28:1838-46.”. Mov Disord.

Goldman, SM, F Kamel, GW Ross, SA Jewell, GS Bhudhikanok, D Umbach, C Marras, et al. 2012. “Head Injury, α-Synuclein Rep1, and Parkinson’s Disease. Ann Neurol 2012;71:40-8.”. Ann Neurol.

Mizuno, Y, M Yamamoto, S Kuno, K Hasegawa, N Hattori, T Kagimura, A Sarashina, et al. 2012. “Pramipexole ER Study Group. Efficacy and Safety of Extended- versus Immediate-Release Pramipexole in Japanese Patients With Advanced and L-Dopa-Undertreated Parkinson Disease: A Double-Blind, Randomized Trial. Clin Neuropharmacol 2012;35:174-81.”. Clin Neuropharmacol.